{"doi":"10.1001/jamaoncol.2020.1847","title":"What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?","abstract":null,"journal":"JAMA Oncology","year":2020,"id":610096,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":260185,"name":"Derek Shyr","orcid":"0000-0002-2345-3390","position":1,"is_corresponding":false},{"id":105129,"name":"Yu Shyr","orcid":"0000-0003-2086-9670","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?","abstract":"Our website uses cookies to enhance your experience. By continuing to use our site, or clicking \"Continue,\" you are agreeing to our Cookie Policy | Continue","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32701117","pmcid":"PMC7780730","openalex_id":"https://openalex.org/W3044414572","authors":[],"funders":[{"funder_name":"NIGMS NIH HHS","grant_id":"T32 GM135117","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P50 CA098131","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U24 CA163056","title":null}],"total_grants":3,"fwci":1.3994,"citation_percentile":0.82943243,"influential_citations":0,"citation_trend":[{"year":2020,"count":2},{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":1},{"year":2025,"count":3},{"year":2026,"count":1}],"oa_status":"green","license":null,"oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7780730","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7780730","host_type":"repository"},{"url":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2768221/jamaoncology_shyr_2020_ed_200007_1599154401.19006.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1001/jamaoncol.2020.1847","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32701117","host_type":"repository"}],"fields_of_study":["Statistical Methods in Clinical Trials","Health Systems, Economic Evaluations, Quality of Life","Cancer Genomics and Diagnostics"],"mesh_terms":["Breast Neoplasms","Follow-Up Studies","Humans","Biomarkers","Neoadjuvant Therapy"],"keywords":["Medicine","Surrogate endpoint","Endpoint Determination","End point","Cancer","MEDLINE","Clinical trial","Oncology","Internal medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T19:21:42.563339Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}